KEMPHARM, INC Contracts & Agreements
125 Contracts & Agreements
- Business Finance (68 contracts)
- Business Formation (1)
- Business Operations (5)
- Human Resources (33)
- Mergers & Acquisitions (2)
- Real Estate (4)
- Uncategorized (12)
- Form of Warrant (Filed With SEC on November 20, 2023)
- Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra Therapeutics, Inc., Computershare, Inc., and Computershare Trust Company, N.A (Filed With SEC on November 20, 2023)
- Employment Agreement, effective as of October 10, 2023,between Zevra Therapeutics, Inc. and Neil F. McFarlane (Filed With SEC on October 10, 2023)
- Agreement and Plan of Merger dated as of August 30, 2023 by and among Zevra Therapeutics, Inc., Aspen Z Merger Sub, Inc., and Acer Therapeutics Inc (Filed With SEC on August 31, 2023)
- Bridge Loan Agreement dated as of August 30, 2023 by and between Zevra Therapeutics, Inc. and Acer Therapeutics Inc (Filed With SEC on August 31, 2023)
- Loan Purchase Agreement dated as of August 30, 2023 by and among Zevra Therapeutics, Inc., and Nantahala Capital Management, LLC and the other sellers party thereto (Filed With SEC on August 31, 2023)
- Note Purchase Agreement dated as of August 30, 2023 by and among Zevra Therapeutics, Inc., and Nantahala Capital Management, LLC and the other sellers party thereto (Filed With SEC on August 31, 2023)
- Registration Rights Agreement dated as of August 30, 2023 by and among Zevra Therapeutics, Inc., and each of the sellers party thereto (Filed With SEC on August 31, 2023)
- Voting and Support Agreement dated as of August 30, 2023 by and among Zevra Therapeutics, Inc., Aspen Z Merger Sub, Inc., and certain stockholders of Acer Therapeutics Inc (Filed With SEC on August 31, 2023)
- Ninth Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on August 14, 2023)
- Agreement Regarding Employment Terms, dated as of May 13, 2023, between Zevra Therapeutics, Inc. and Christal M.M. Mickle (Filed With SEC on May 15, 2023)
- Transition Agreement, dated as of May 6, 2023, between Zevra Therapeutics, Inc. and Richard W. Pascoe (Filed With SEC on May 8, 2023)
- Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 7, 2023)
- EighthAmended and Restated Non-Employee Director Compensation Policyeffective February 15, 2023 (Filed With SEC on March 7, 2023)
- 2023 Employment Inducement Award Plan and forms of award agreements thereunder (Filed With SEC on March 7, 2023)
- Amendment to Employment Agreement, dated as of January 6, 2023, between KemPharm, Inc. and Richard W. Pascoe (Filed With SEC on January 9, 2023)
- Transition Agreement, dated as of January 4, 2023, as amended, between KemPharm, Inc. and Travis C. Mickle, Ph.D (Filed With SEC on January 9, 2023)
- Consulting Agreement, dated as of January 6, 2023, between KemPharm, Inc. and Travis C. Mickle, Ph.D (Filed With SEC on January 9, 2023)
- Revolving Loan Agreement dated May 31, 2022 by and among KemPharm, Inc. and Ameris Bank, as lender (Filed With SEC on June 1, 2022)
- Asset Purchase Agreement by and among KemPharm, Inc., KemPharm Denmark A/S and Orphazyme A/S in restructuring, dated May 15, 2022 (Filed With SEC on May 16, 2022)
- Seventh Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 12, 2022)
- Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 31, 2022)
- Executive Employment Agreement by and between the Registrant and Richard W. Pascoe, dated as of November 5, 2021 (Filed With SEC on November 10, 2021)
- Amendment No. 1 to Collaboration and License Agreement, effective as of April 8, 2021, by and between the Company and Commave Therapeutics SA (Filed With SEC on August 13, 2021)
- Amended and Restated 2014 Equity Incentive Plan (Filed With SEC on August 13, 2021)
- 2021 Employee Stock Purchase Plan (Filed With SEC on August 13, 2021)
- Equity Distribution Agreement, dated July 2, 2021, by and among KemPharm, Inc., JMP Securities LLC and RBC Capital Markets, LLC (Filed With SEC on July 2, 2021)
- Form of Inducement Warrant (Filed With SEC on June 23, 2021)
- Form of Inducement Letter (Filed With SEC on June 23, 2021)
- Specimen stock certificate evidencing shares of Common Stock (Filed With SEC on March 12, 2021)
- Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 12, 2021)
- Sixth Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on March 12, 2021)
- Payoff letter, dated as of February 8, 2021, by and among the Company and the lenders named therein (Filed With SEC on February 9, 2021)
- Form of Inducement Warrant (Filed With SEC on January 26, 2021)
- Form of Inducement Letter (Filed With SEC on January 26, 2021)
- Form of Common Stock Purchase Warrant and schedule of holders (Filed With SEC on January 13, 2021)
- Series A Common Stock Purchase Warrant for Underwriter (Filed With SEC on January 13, 2021)
- Amendment to Senior Secured Convertible Notes and Amendment to Warrant, dated as of January 12, 2021, by and among the Company, Deerfield Private Design Fund III, L.P. and... (Filed With SEC on January 13, 2021)
- Form of Underwriting Agreement (Filed With SEC on January 5, 2021)
- Amendment to Facility Agreement, Notes and to December 2020 Exchange Agreement, dated as of December 24, 2020, by and among KemPharm, Inc., Deerfield Private Design Fund III, L.P.... (Filed With SEC on December 28, 2020)
- Joinder Agreement, dated as of December 23, 2020, by and between KemPharm, Inc. and Delaware Street Capital Master Fund, L.P (Filed With SEC on December 28, 2020)
- Joinder Agreement, dated as of December 23, 2020, by and between KemPharm, Inc. and M. Kingdon Offshore Master Fund, LP (Filed With SEC on December 28, 2020)
- December 2020 Exchange Agreement and Amendment to Facility Agreement, Notes and Investors Rights Agreement, dated as of December 20, 2020, by and among KemPharm, Inc., Deerfield... (Filed With SEC on December 21, 2020)
- Form of Underwriting Agreement (Filed With SEC on December 21, 2020)
- Form of Common Stock Warrant (Filed With SEC on December 21, 2020)
- Form of Pre-Funded Warrant (Filed With SEC on December 21, 2020)
- Termination of Agreement of Sublease, by and between KemPharm, Inc. and Ciber Global, LLC, dated as of October 22, 2020 (Filed With SEC on October 30, 2020)
- Amended and Restated Bylaws of KemPharm, Inc., effective as of July 15, 2020 (Filed With SEC on July 17, 2020)
- Fifth Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on June 24, 2020)
- Registration Rights Agreement dated February 28, 2019 by and between the Company and Lincoln Park Capital Fund, LLC (incorporated herein by reference to the Registrant's Annual... (Filed With SEC on February 28, 2020)
- Agreement to Sublease, by and between KemPharm, Inc. and Ciber Global, LLC, dated as of January 15, 2020 (Filed With SEC on February 28, 2020)
- Purchase Agreement, dated as of February 17, 2020, by and between KemPharm, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on February 18, 2020)
- Registration Rights Agreement, dated as of February 17, 2020, by and between KemPharm, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on February 18, 2020)
- Amendment to Senior Secured Convertible Notes and Amendment to Warrant, dated as of February 17, 2020, by and among KemPharm, Inc. and the noteholders party thereto (Filed With SEC on February 18, 2020)
- January 2020 Exchange Agreement, dated as of January 12, 2020, by and between KemPharm, Inc. and M. Kingdon Offshore Master Fund, LP (Filed With SEC on January 13, 2020)
- Senior Secured Convertible Note, dated as of January 13, 2020 (Filed With SEC on January 13, 2020)
- Amendment to December 2019 Notes and Consent, dated as of January 12, 2020, by and among KemPharm, Inc. and the signatories party thereto (Filed With SEC on January 13, 2020)
- December 2019 Exchange Agreement and Amendment to Facility Agreement, Senior Secured Convertible Notes and Warrants, dated as of December 17, 2019, by and among KemPharm, Inc.,... (Filed With SEC on December 18, 2019)
- Amendment to September 2019 Exchange Agreement and Amendment to Facility Agreement, dated as of December 17, 2019, by and among KemPharm, Inc., Deerfield Private Design Fund III,... (Filed With SEC on December 18, 2019)
- Form of Senior Secured Convertible Note, with a schedule of noteholders (Filed With SEC on December 18, 2019)
- Amended and Restated Senior Secured Convertible Note issued to Deerfield Private Design Fund III, L.P., dated as of December 18, 2019 (Filed With SEC on December 18, 2019)
- Amended and Restated Guaranty and Security Agreement, dated as of December 18, 2019, by and among KemPharm, Inc., each other Grantor party thereto, each Guarantor party thereto... (Filed With SEC on December 18, 2019)
- Amendment to Facility Agreement, by and between Registrant and Deerfield Private Design Fund III, L.P., dated August 16, 2019 (Filed With SEC on November 14, 2019)
- Amendment to Facility Agreement, by and between Registrant and Deerfield Private Design Fund III, L.P., dated August 23, 2019 (Filed With SEC on November 14, 2019)
- Amendment to Facility Agreement, by and between Registrant and Deerfield Private Design Fund III, L.P., dated August 30, 2019 (Filed With SEC on November 14, 2019)
- Fourth Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on November 14, 2019)
- Agreement to Terminate CLA, by and between MonoSol Rx, LLC and the Registrant, dated as of March 20, 2012 (Filed With SEC on November 14, 2019)
- September 2019 Exchange Agreement and Amendment to Facility Agreement, dated as of September 3, 2019, by and among KemPharm, Inc., Deerfield Private Design Fund III, L.P. and... (Filed With SEC on September 4, 2019)
- Collaboration and License Agreement, dated as of September 3, 2019, by and between KemPharm, Inc. and Boston Pharmaceuticals Holdings SA (Filed With SEC on September 4, 2019)
- Amendment to Facility Agreement, by and between Registrant and Deerfield Private Design Fund III, L.P., dated June 3, 2019 (Filed With SEC on August 13, 2019)
- Amendment to Facility Agreement, by and between Registrant and Deerfield Private Design Fund III, L.P., dated June 17, 2019 (Filed With SEC on August 13, 2019)
- Amendment to Facility Agreement, by and between Registrant and Deerfield Private Design Fund III, L.P., dated June 24, 2019 (Filed With SEC on August 13, 2019)
- Amendment to Facility Agreement, by and between Registrant and Deerfield Private Design Fund III, L.P., dated June 28, 2019 (Filed With SEC on August 13, 2019)
- Amendment to Facility Agreement, by and between Registrant and Deerfield Private Design Fund III, L.P., dated July 15, 2019 (Filed With SEC on August 13, 2019)
- Amendment to Facility Agreement, by and between Registrant and Deerfield Private Design Fund III, L.P., dated July 31, 2019 (Filed With SEC on August 13, 2019)
- Amendment to Facility Agreement, by and between Registrant and Deerfield Private Design Fund III, L.P., dated August 9, 2019 (Filed With SEC on August 13, 2019)
- Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under 2014 Equity Incentive Plan (Filed With SEC on May 14, 2019)
- Registration Rights Agreement dated February 28, 2019 by and between the Company and Lincoln Park Capital Fund, LLC (Filed With SEC on March 1, 2019)
- Seventh Amendment to Senior Secured Convertible Note and Sixth Amendment to Warrant, dated February 28, 2019, between the Company and Deerfield Private Design Fund III, L.P (Filed With SEC on March 1, 2019)
- Amended Non-Employee Director Compensation Policy (Filed With SEC on March 1, 2019)
- Warrant to Purchase Shares of Common Stock issued to KVK Tech, Inc. dated October 25, 2018 (Filed With SEC on March 1, 2019)
- Purchase Agreement dated February 28, 2019 by and between the Company and Lincoln Park Capital Fund, LLC (Filed With SEC on March 1, 2019)
- Collaboration and License Agreement by and between the Company and KVK Tech, Inc. dated as of October 25, 2018 (Filed With SEC on March 1, 2019)
- Supplemental Indenture, dated November 20, 2018, between KemPharm, Inc. and U.S. Bank National Association, as trustee (Filed With SEC on November 20, 2018)
- Amendment to Convertible Note and Warrant, dated November 20, 2018, between KemPharm, Inc. and Deerfield Private Design Fund III, L.P (Filed With SEC on November 20, 2018)
- Separation Agreement and General Release by and between the Registrant and Daniel L. Cohen, dated as of September 5, 2018 (Filed With SEC on November 9, 2018)
- Underwriting Agreement by and among KemPharm, Inc. and RBC Capital Markets, LLC, dated October 5, 2018 (Filed With SEC on October 5, 2018)
- Exchange Agreement, dated as of October 5, 2018, by and among KemPharm, Inc., Deerfield Private Design Fund III, L.P. and Deerfield Special Situations Fund, L.P (Filed With SEC on October 5, 2018)
- Common Stock Sales Agreement, dated September 4, 2018, by and between KemPharm, Inc. and RBC Capital Markets, LLC (Filed With SEC on September 4, 2018)
- Facility Agreement Waiver and Fifth Amendment to Senior Secured Convertible Note by and between the Company and Deerfield Private Design Fund III, L.P., dated as of June 11, 2018 (Filed With SEC on June 11, 2018)
- KemPharm, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on March 30, 2018)
- Lease Agreement, by and between KemPharm, Inc. and the Board of Regents, State of Iowa for the Use and Benefit of the University of Iowa, dated as of September 5, 2017 (Filed With SEC on March 30, 2018)
- Office Lease CELEBRATION OFFICE CENTER II 1170 CELEBRATION BOULEVARD CELEBRATION, FLORIDA Between BRE/COH FL LLC, a Delaware limited liability company as Landlord, and KEMPHARM,... (Filed With SEC on March 10, 2017)
- FIRST AMENDMENT (Filed With SEC on March 10, 2017)
- SECOND AMENDMENT (Filed With SEC on March 10, 2017)
- THIRD AMENDMENT (Filed With SEC on March 10, 2017)
- LEASE DOCUMENT FOR THE UNIVERSITY OF IOWA BIOVENTURES CENTER (Filed With SEC on November 10, 2016)
- KEMPHARM, INC. COMMON STOCK SALES AGREEMENT (Filed With SEC on October 3, 2016)
- FOURTH AMENDMENT TO SENIOR SECURED CONVERTIBLE NOTE AND WARRANT (Filed With SEC on October 3, 2016)
- KemPharm, Inc. Employment Agreement Daniel L. Cohen Effective as of April 13, 2016 KemPharm, Inc. Employment Agreement (Filed With SEC on May 13, 2016)
- KemPharm, Inc. Amended and Restated Employment Agreement Sven Guenther Effective as of April 13, 2016 KemPharm, Inc. Amended and Restated Employment Agreement (Filed With SEC on May 13, 2016)
- KemPharm, Inc. Non-Employee Director Compensation Policy (Filed With SEC on March 16, 2016)
- SECOND AMENDMENT TO SENIOR SECURED CONVERTIBLE NOTE AND WARRANT (Filed With SEC on January 11, 2016)
- SECOND AMENDMENT TO FACILITY AGREEMENT (Filed With SEC on December 18, 2015)
- SECONDAMENDMENT TO FACILITY AGREEMENT (Filed With SEC on December 18, 2015)
- Amendment to Employment Agreement (Filed With SEC on November 13, 2015)
- Amendment to Amended and Restated Employment Agreement (Filed With SEC on November 13, 2015)
- Amendment to Amended and Restated Employment Agreement (Filed With SEC on November 13, 2015)
- Amendment to Employment Agreement (Filed With SEC on November 13, 2015)
- Amendment to Employment Agreement (Filed With SEC on November 13, 2015)
- KemPharm, Inc. Employment Agreement (Filed With SEC on August 14, 2015)
- KemPharm, Inc. Amended and Restated Employment Agreement (Filed With SEC on August 14, 2015)
- KemPharm, Inc. Amended and Restated Employment Agreement (Filed With SEC on August 14, 2015)
- KemPharm, Inc. Employment Agreement Tracy Woody Dated March 30, 2015 KemPharm, Inc. Employment Agreement (Filed With SEC on May 29, 2015)
- AGREEMENT TO TERMINATE CLA BETWEEN MONOSOL RX, LLC AND KEMPHARM, INC. DATED AS OF MARCH 20, 2012 Agreement to Terminate CLA Between MONOSOL, RX and KemPharm, (Filed With SEC on April 9, 2015)
- [Number of Shares] KEMPHARM, INC. CommonStock UNDERWRITING AGREEMENT (Filed With SEC on April 3, 2015)
- ASSET PURCHASE AGREEMENT between SHIRE LLC and TRAVIS C.MICKLE, PH.D., AND KEMPHARM, INC. dated as of March 21, 2012 (Filed With SEC on April 3, 2015)
- MATERIAL SUPPLY AGREEMENT (Filed With SEC on April 3, 2015)
- AGREEMENT TO TERMINATE CLA BETWEEN MONOSOL RX, LLC AND KEMPHARM, INC. DATED AS OF MARCH 20, 2012 Agreement to Terminate CLA Between MONOSOL, RX and KemPharm, (Filed With SEC on April 3, 2015)
- KEMPHARM, INC. INCENTIVE STOCK PLAN (Filed With SEC on April 3, 2015)
- KEMPHARM, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:NOVEMBER 7, 2014 APPROVED BY THE STOCKHOLDERS:APRIL 1, 2015 IPO DATE/EFFECTIVE DATE: , 2015 (Filed With SEC on April 3, 2015)
- ASSET PURCHASE AGREEMENT between SHIRE LLC and TRAVIS C.MICKLE, PH.D., AND KEMPHARM, INC. dated as of March 21, 2012 (Filed With SEC on March 11, 2015)
- MATERIAL SUPPLY AGREEMENT (Filed With SEC on March 11, 2015)
- FACILITY AGREEMENT (Filed With SEC on March 11, 2015)
- FIRST AMENDMENT TO FACILITY AGREEMENT, SENIOR SECURED CONVERTIBLE NOTE AND WARRANT (Filed With SEC on March 11, 2015)